Previous research had suggested the existence of such a gene, but with vague and varied suggestions as to its exact location. Dr Clapcote believes that the team’s preliminary work should make it easier to confirm and locate the gene involved. If successful, they plan to apply the new gene discovery approach to other families with multiple cases of schizophrenia. The identified genes may include suitable targets for new drugs, which the team is hopeful will treat the causes of the disease, not just the symptoms, and with fewer side effects.
Dr Clapcote is available for interview.
For further information, please contact:
Jo Kelly, Campus PR tel 0113 357 2100, mob 07980 267756 email firstname.lastname@example.org
University of Leeds Press Office, tel 0113 343 4031
Notes for Editors
The Faculty of Biological Sciences at the University of Leeds is one of the largest in the UK, with over 150 academic staff and over 400 postdoctoral fellows and postgraduate students. The Faculty is ranked 4th in the UK (Nature Journal, 457 (2009) doi :10.1038/457013a) based on results of the 2008 Research Assessment Exercise (RAE). The RAE feedback noted that “virtually all outputs were assessed as being recognized internationally, with many (60%) being internationally excellent or world-leading” in quality. The Faculty’s research grant portfolio totals some £60M and funders include charities, research councils, the European Union and industry. www.fbs.leeds.ac.uk
The University of Leeds is one of the largest higher education institutions in the UK with more than 30,000 students from 130 countries. With a turnover approaching £450m, Leeds is one of the top ten research universities in the UK, and a member of the Russell Group of research-intensive universities. It was placed 80th in the 2007 Times Higher Education world universities league table. The University’s vision is to secure a place among the world’s top 50 by 2015. www.leeds.ac.uk
For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including the first antibiotic penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century. www.mrc.ac.uk